Lyell Immunopharma, Inc. — Director's Dealing 2026

Feb 11, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2026-02-10

Reporting Person: Bulis Veronica Sanchez (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-10	Common Stock	A	8750	—	Acquired	15891	Direct
2026-02-10	Common Stock	S	254	$23.12	Disposed	15637	Direct

Footnotes

F1: Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan. 12.5% of the total number of restricted stock units will vest on August 9, 2026, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.

F2: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.